• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    CAI International, Inc. Announces the Completion of the Sale of its Railcar Fleet to Infinity Transportation

    12/29/20 3:23:00 PM ET
    $CAI
    Medical Specialities
    Health Care
    Get the next $CAI alert in real time by email

    SAN FRANCISCO--(BUSINESS WIRE)--CAI International, Inc. (“CAI” or the “Company”) (NYSE: CAI), is pleased to announce the closing of its previously reported agreement to sell all of its remaining railcar fleet to Infinity Transportation for $228.1 million.

    Timothy Page, Interim President and Chief Executive Officer of CAI, commented, “The closing of the sale of our remaining railcar fleet completes the commitment we made to divest our non-core assets and will allow us to maximize shareholder returns by focusing all of our resources on our core container leasing business.”

    About CAI International, Inc.

    CAI is one of the world’s leading transportation finance companies. As of September 30, 2020, CAI operated a worldwide fleet of approximately 1.7 million CEUs of containers. CAI operates through 14 offices located in 12 countries including the United States.

    About Infinity Transportation

    Infinity Transportation, a subsidiary of Global Atlantic Financial Group, provides net and full-service leases as well as other structured financing solutions that address the logistical and financial needs of its clients in the rail, aviation, and intermodal industries. Infinity Transportation manages a large, diverse portfolio of transportation assets and is led by a veteran management team with a broad range of technical expertise, asset-level knowledge and transaction experience across transportation operations, maintenance and finance.

    Get the next $CAI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CAI

    DatePrice TargetRatingAnalyst
    4/13/2026$28.00Buy
    Jefferies
    4/10/2026$21.00Neutral
    Piper Sandler
    4/1/2026$27.00Buy
    Goldman
    2/17/2026$26.00Outperform
    Robert W. Baird
    12/2/2025$28.00Hold
    Canaccord Genuity
    7/14/2025$31.00Buy
    BofA Securities
    7/14/2025$31.00Overweight
    Analyst
    7/14/2025$32.00Buy
    Guggenheim
    More analyst ratings

    $CAI
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Caris Life Sciences Inc.

    SCHEDULE 13G/A - Caris Life Sciences, Inc. (0002019410) (Subject)

    4/7/26 1:21:16 PM ET
    $CAI
    Medical Specialities
    Health Care

    Caris Life Sciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation

    8-K - Caris Life Sciences, Inc. (0002019410) (Filer)

    4/2/26 4:28:46 PM ET
    $CAI
    Medical Specialities
    Health Care

    Caris Life Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Caris Life Sciences, Inc. (0002019410) (Filer)

    2/26/26 4:11:03 PM ET
    $CAI
    Medical Specialities
    Health Care

    $CAI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Caris Life Sciences to Report First Quarter 2026 Financial Results on May 7, 2026

    IRVING, Texas, April 20, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced it will report first quarter 2026 financial results on Thursday, May 7, 2026. Caris Life Sciences will host a live webcast at 3:30 p.m. CT (4:30 p.m. ET) to discuss the financial results.Webcast Details:Date: Thursday, May 7, 2026Time: 3:30 p.m. CT (4:30 p.m. ET)Live Webcast: https://edge.media-server.com/mmc/p/6iwr2xf8/A replay of the webcast will be available shortly after the conclusion

    4/20/26 8:30:00 AM ET
    $CAI
    Medical Specialities
    Health Care

    Caris Precision Oncology Alliance Welcomes UCSF Helen Diller Family Comprehensive Cancer Center

    IRVING, Texas, April 17, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that the UCSF Helen Diller Family Comprehensive Cancer Center has joined the Caris Precision Oncology Alliance® (POA). The Caris POA is a global network of leading cancer centers and research groups that collaborate to advance precision oncology and biomarker-driven research. "Welcoming UCSF Helen Diller Family Comprehensive Cancer Center to the Caris Precision Oncology Alliance underscores

    4/17/26 8:30:00 AM ET
    $CAI
    Medical Specialities
    Health Care

    Caris Life Sciences Right-In-Time Clinical Trial Solution Expands Access to Precision Oncology Trials for Historically Underserved Cancer Patients

    Comprehensive molecular profiling paired with biomarker-driven trial matching provides cancer patients with a complete pathway from diagnosis to treatment across more than 600 locations nationwideIRVING, Texas, April 15, 2026 /PRNewswire/ -- Caris Life Sciences®, Inc. (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today highlighted the growing urgency of closing the geographic gap in cancer clinical trial access and the role its Right-In-Time (RIT) clinical trial solution plays in bringing biomarker-driven trials to community oncology practices nationwide.

    4/15/26 8:30:00 AM ET
    $CAI
    Medical Specialities
    Health Care

    $CAI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies initiated coverage on Caris Life Sciences with a new price target

    Jefferies initiated coverage of Caris Life Sciences with a rating of Buy and set a new price target of $28.00

    4/13/26 8:51:07 AM ET
    $CAI
    Medical Specialities
    Health Care

    Piper Sandler initiated coverage on Caris Life Sciences with a new price target

    Piper Sandler initiated coverage of Caris Life Sciences with a rating of Neutral and set a new price target of $21.00

    4/10/26 8:31:01 AM ET
    $CAI
    Medical Specialities
    Health Care

    Goldman initiated coverage on Caris Life Sciences with a new price target

    Goldman initiated coverage of Caris Life Sciences with a rating of Buy and set a new price target of $27.00

    4/1/26 8:30:56 AM ET
    $CAI
    Medical Specialities
    Health Care

    $CAI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President Spetzler David Baxley was granted 83,162 shares, increasing direct ownership by 18% to 543,939 units (SEC Form 4)

    4 - Caris Life Sciences, Inc. (0002019410) (Issuer)

    3/10/26 5:59:58 PM ET
    $CAI
    Medical Specialities
    Health Care

    SEC Form 4 filed by Caris Life Sciences Inc.

    4 - Caris Life Sciences, Inc. (0002019410) (Issuer)

    3/10/26 6:01:21 PM ET
    $CAI
    Medical Specialities
    Health Care

    Officer Denton John Russel was granted 63,971 shares, increasing direct ownership by 52% to 187,562 units (SEC Form 4)

    4 - Caris Life Sciences, Inc. (0002019410) (Issuer)

    3/10/26 6:00:25 PM ET
    $CAI
    Medical Specialities
    Health Care

    $CAI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Denton John Russel bought $100,793 worth of shares (4,184 units at $24.09) (SEC Form 4)

    4 - Caris Life Sciences, Inc. (0002019410) (Issuer)

    11/10/25 8:12:42 AM ET
    $CAI
    Medical Specialities
    Health Care

    President Spetzler David Baxley bought $9,540 worth of shares (400 units at $23.85), increasing direct ownership by 0.09% to 460,777 units (SEC Form 4)

    4 - Caris Life Sciences, Inc. (0002019410) (Issuer)

    11/10/25 8:11:33 AM ET
    $CAI
    Medical Specialities
    Health Care

    Officer Denton John Russel returned $4,431,078 worth of shares to the company (238,230 units at $18.60), was granted 99,321 shares and bought $157,500 worth of shares (7,500 units at $21.00), decreasing direct ownership by 52% to 123,591 units (SEC Form 4)

    4 - Caris Life Sciences, Inc. (0002019410) (Issuer)

    6/23/25 6:34:51 PM ET
    $CAI
    Medical Specialities
    Health Care

    $CAI
    Financials

    Live finance-specific insights

    View All

    Caris Life Sciences to Report First Quarter 2026 Financial Results on May 7, 2026

    IRVING, Texas, April 20, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced it will report first quarter 2026 financial results on Thursday, May 7, 2026. Caris Life Sciences will host a live webcast at 3:30 p.m. CT (4:30 p.m. ET) to discuss the financial results.Webcast Details:Date: Thursday, May 7, 2026Time: 3:30 p.m. CT (4:30 p.m. ET)Live Webcast: https://edge.media-server.com/mmc/p/6iwr2xf8/A replay of the webcast will be available shortly after the conclusion

    4/20/26 8:30:00 AM ET
    $CAI
    Medical Specialities
    Health Care

    Caris Life Sciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 26

    IRVING, Texas, Feb. 9, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026. Caris Life Sciences will host a conference call and live webcast at 3:30 p.m. CT (4:30 p.m. ET) to discuss the financial results. Conference Call Details: Date: Thursday, February 26, 2026Time: 3:30 p.m. CT (4:30 p.m. ET)Live Webcast: https://edge.media-server.com/mmc/p/49czfgs4 A replay of th

    2/9/26 8:30:00 AM ET
    $CAI
    Medical Specialities
    Health Care

    Caris Life Sciences to Report Third Quarter 2025 Financial Results on November 5, 2025

    IRVING, Texas, Oct. 23, 2025 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced it will report third quarter 2025 financial results on Wednesday, November 5, 2025. Caris Life Sciences will host a conference call and live webcast at 3:30 p.m. CT (4:30 p.m. ET) to discuss the financial results. Conference Call Details: Date: Wednesday, November 5, 2025Time: 3:30 p.m. CT (4:30 p.m. ET)Live Webcast: https://edge.media-server.com/mmc/p/uwjxydsa A replay of the webcast will

    10/23/25 8:30:00 AM ET
    $CAI
    Medical Specialities
    Health Care

    $CAI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by CAI International, Inc. (Amendment)

    SC 13G/A - CAI International, Inc. (0001388430) (Subject)

    12/10/21 10:00:15 AM ET
    $CAI
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by CAI International, Inc.

    SC 13G - CAI International, Inc. (0001388430) (Subject)

    11/12/21 9:17:56 AM ET
    $CAI
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by CAI International, Inc.

    SC 13G - CAI International, Inc. (0001388430) (Subject)

    10/7/21 4:07:36 PM ET
    $CAI
    Medical Specialities
    Health Care